Efficacy and tolerability of escitalopram in treatment of major depressive disorder with anxiety symptoms: a 24-week, open-label, prospective study in Chinese population

References

• FavaMRushAJAlpertJEDifference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D reportAm J Psychiatry2008165334235118172020
   PubMed Web of Science ®Google Scholar
• ZimmermanMMcDermutWMattiaJIFrequency of anxiety disorders in psychiatric outpatients with major depressive disorderAm J Psychiatry200015781337134010910803
   PubMed Web of Science ®Google Scholar
• RushAJZimmermanMWisniewskiSRComorbid psychiatric disorders in depressed outpatients: demographic and clinical featuresJ Affect Disord2005871435515894381
   PubMed Web of Science ®Google Scholar
• FarabaughAAlpertJWisniewskiSRCognitive therapy for anxious depression in STAR (*) D: What have we learned?J Affect Disord2012142121321822877961
   PubMed Web of Science ®Google Scholar
• BelzerKSchneierFRComorbidity of anxiety and depressive disorders: issues in conceptualization, assessment, and treatmentJ Psychiatr Pract200410529630615361744
   PubMedGoogle Scholar
• NovickJSStewartJWWisniewskiSRClinical and demographic features of atypical depression in outpatients with major depressive disorder: preliminary findings from STAR* DJ Clin Psychiatry20056681002101116086615
   PubMed Web of Science ®Google Scholar
• Diagnostic and statistical manual of mental disorders5th edArlington, VAAmerican Psychiatric Publishing: American Psychiatric Association2013
   Google Scholar
• IonescuDFNiciuMJHenterIDZarateCADefining anxious depression: a review of the literatureCNS Spectr201318525226023507190
   PubMed Web of Science ®Google Scholar
• FavaMAlpertJECarminCNClinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*DPsychol Med20043471299130815697056
   PubMed Web of Science ®Google Scholar
• DomschkeKDeckertJAroltVBauneBTAnxious versus non-anxious depression: difference in treatment outcomeJ Psychopharmacol201024462162218838496
   PubMed Web of Science ®Google Scholar
• KesslerRCNelsonCBMcGonagleKALiuJSwartzMBlazerDGComorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity SurveyBr J Psychiatry Suppl1996301730
   PubMedGoogle Scholar
• ShiSSZhangMYWuWYMulti-center study of the clinical features in depression comorbidity with anxiety disordersShanghai Arch Psychiatry2009214198202
   Google Scholar
• KesslerRCDuPontRLBerglundPWittchenHUImpairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveysAm J Psychiatry1999156121915192310588405
   PubMed Web of Science ®Google Scholar
• ChenYFChinese classification of mental disorders (CCMD-3): towards integration in international classificationPsychopathology2002352–317117512145505
   PubMed Web of Science ®Google Scholar
• WuZChenJYuanCDifference in remission in a Chinese population with anxious versus nonanxious treatment-resistant depression: a report of OPERATION studyJ Affect Disord2013150383483923570952
   PubMed Web of Science ®Google Scholar
• MohamedSOsatukeKAslamMKasckowJEscitalopram for comorbid depression and anxiety in elderly patients: a 12-week, open-label, flexible-dose, pilot trialAm J Geriatr Pharmacother20064320120917062320
   PubMedGoogle Scholar
• BallengerJCAnxiety and depression: optimizing treatmentsPrim Care Companion J Clin Psychiatry200023717915014652
   PubMedGoogle Scholar
• DahlAARavindranAAllgulanderCKutcherSPAustinCBurtTSertraline in generalized anxiety disorder: efficacy in treating the psychic and somatic anxiety factorsActa Psychiatr Scand2005111642943515877709
   PubMed Web of Science ®Google Scholar
• WaughJGoaKLEscitalopram: a review of its use in the management of major depressive and anxiety disordersCNS Drugs200317534336212665392
   PubMed Web of Science ®Google Scholar
• HoschlCSvestkaJEscitalopram for the treatment of major depression and anxiety disordersExpert Rev Neurother20088453755218416657
   PubMedGoogle Scholar
• CiprianiAFurukawaTASalantiGComparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysisLancet2009373966574675819185342
   PubMed Web of Science ®Google Scholar
• BoulengerJPHermesAHuusomAKWeillerEBaseline anxiety effect on outcome of SSRI treatment in patients with severe depression: escitalopram vs paroxetineCurr Med Res Opin201026360561420067433
   PubMed Web of Science ®Google Scholar
• BoulengerJPHuusomAKFloreaIBaekdalTSarchiaponeMA comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patientsCurr Med Res Opin20062271331134116834832
   PubMed Web of Science ®Google Scholar
• BurkeWJGergelIBoseAFixed-dose trial of the single isomer SSRI escitalopram in depressed outpatientsJ Clin Psychiatry200263433133612000207
   PubMed Web of Science ®Google Scholar
• MaityNGhosalMKGuptaASilAChakrabortySChatterjeeSClinical effectiveness and safety of escitalopram and desvenlafaxine in patients of depression with anxiety: a randomized, open-label controlled trialIndian J Pharmacol201446443343725097285
   PubMed Web of Science ®Google Scholar
• Association APDiagnostic and Statistical Manual of Mental Disorders (DSM)Washington, DCAmerican psychiatric association1994143147
   Google Scholar
• MontgomerySAAsbergMA new depression scale designed to be sensitive to changeBr J Psychiatry19791344382389444788
   PubMed Web of Science ®Google Scholar
• YuhuaTZMHamilton Anxiety Rating Scale (HAMA)Shanghai Arch Psychiatry198426467
   Google Scholar
• SajatovicMRamirezLFRating Scales in Mental Health3rd edBaltimore, MDJHU Press2012
   Google Scholar
• BusnerJTargumSDThe clinical global impressions scale: applying a research tool in clinical practicePsychiatry (Edgmont)2007472837
   PubMedGoogle Scholar
• ColeJCMotivalaSJDangJStructural validation of the Hamilton depression rating scaleJ Psychopathol Behav200426414
   Web of Science ®Google Scholar
• LenertLASherbourneCDSugarCWellsKBEstimation of utilities for the effects of depression from the SF-12Med Care200038776377010901359
   PubMed Web of Science ®Google Scholar
• GandekBWareJEAaronsonNKCross-validation of item selection and scoring for the SF-12 health survey in nine countries: results from the IQOLA project. International quality of life assessmentJ Clin Epidemiol19985111117111789817135
   PubMed Web of Science ®Google Scholar
• MaoPXTangYLJiangFEscitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese populationDepress Anxiety2008251465417149753
   PubMed Web of Science ®Google Scholar
• KennedySHAndersenHFLamRWEfficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysisJ Psychiatry Neurosci200631212213116575428
   PubMed Web of Science ®Google Scholar
• MontgomerySAAndersenHFEscitalopram versus venlafaxine XR in the treatment of depressionInt Clin Psychopharmacol200621529730916877901
   PubMed Web of Science ®Google Scholar
• WoolleySBCardoniAAGoetheJWLast-observation-carried-forward imputation method in clinical efficacy trials: review of 352 antidepressant studiesPharmacotherapy200929121408141619947800
   PubMed Web of Science ®Google Scholar
• Medical Dictionary for Regulatory ActivitiesIntroductory Guide MedDRA Version 15.1. Document MSSO-DI-6003-15.1.0
   Google Scholar
• ColonnaLAndersenHFReinesEHA randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorderCurr Med Res Opin200521101659166816238906
   PubMed Web of Science ®Google Scholar
• ThaseMEChenDEdwardsJRuthAEfficacy of vilazodone on anxiety symptoms in patients with major depressive disorderInt Clin Psychopharmacol201429635135624978955
   PubMed Web of Science ®Google Scholar
• SaveanuREtkinADucheminAMThe international study to predict optimized treatment in depression (iSPOT-D): outcomes from the acute phase of antidepressant treatmentJ Psychiatr Res20156111225586212
   PubMed Web of Science ®Google Scholar
• CiprianiASantilliCFurukawaTAEscitalopram versus other antidepressive agents for depressionCochrane Database Syst Rev20092CD006532
   PubMed Web of Science ®Google Scholar
• KiltsCDWadeAGAndersenHFSchlaepferTEBaseline severity of depression predicts antidepressant drug response relative to escitalopramExpert Opin Pharmacother200910692793619317630
   PubMed Web of Science ®Google Scholar
• KornsteinSGLiDMaoYLarssonSAndersenHFPapakostasGIEscitalopram versus SNRI antidepressants in the acute treatment of major depressive disorder: integrative analysis of four double-blind, randomized clinical trialsCNS Spectr200914632633319668123
   PubMed Web of Science ®Google Scholar
• DemyttenaereKAndersenHFReinesEHImpact of escitalopram treatment on quality of life enjoyment and satisfaction questionnaire scores in major depressive disorder and generalized anxiety disorderInt Clin Psychopharmacol200823527628618703937
   PubMed Web of Science ®Google Scholar
• BandelowBSteinDJDolbergOTAndersenHFBaldwinDSImprovement of quality of life in panic disorder with escitalopram, citalopram, or placeboPharmacopsychiatry200740415215617694478
   PubMed Web of Science ®Google Scholar
• ParkHYLeeBJKimJHBaeJNHahmBJRapid improvement of depression and quality of life with escitalopram treatment in outpatients with breast cancer: a 12-week, open-label prospective trialProg Neuropsychopharmacol Biol Psychiatry201236231832322142651
   PubMed Web of Science ®Google Scholar
• WareJKosinskiMJrTurner-BowkerDGandekBHow to score version 2 of the SF-12 Health Survey (with a supplement documenting version 1)Lincoln, RI, USAQualityMetric. Inc2002
   Google Scholar
• LepolaUMLoftHReinesEHEscitalopram (10–20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary careInt Clin Psychopharmacol200318421121712817155
   PubMed Web of Science ®Google Scholar
• ThaseMELarsenKGReinesEKennedySHThe cardiovascular safety profile of escitalopramEur Neuropsychopharmacol201323111391140023928296
   PubMed Web of Science ®Google Scholar
• ArrollBMacgillivraySOgstonSEfficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysisAnn Fam Med20053544945616189062
   PubMed Web of Science ®Google Scholar
• KirinoEEscitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptabilityPatient Prefer Adherence2012685386123271894
   PubMed Web of Science ®Google Scholar